Clinical Activity and Safety Profile of TGR-1202, a Novel Once Daily PI3K-Delta Inhibitor, Demonstrates Clinical Activity with a Favorable Safety Profile, Lacking Hepatotoxicity in Patients with CLL and B-Cell Lymphoma. By admin / 06/20/2015
Clinical Activity and Safety Profile of TGR-1202 a Novel Once Daily PI3K-Delta Inhibitor, Demonstrates Clinical Activity with a Favorable Safety Profile, Lacking Hepatotoxicity, in Patients with CLL and B-Cell Lymphoma. By admin / 06/14/2015
Ubliuximab +TGR-1202 Demonstrates Activity and Favorable Safety Profile in Relapsed/Refractory B-Cell NHL and High-Risk CLL. By admin / 06/02/2015
Clinical Activity and Safety Profile of TGR-1202, a Novel Once Daily Pi3k Delta Inhibitor, in Patients with CLL and B-Cell Lymphoma. By admin / 06/02/2015
Ublituximab + TGR-1202 Demonstrates Activity and a Favorable Safety Profile in Relapsed/Refractory B-Cell NHL and High-Risk CLL: Phase I Results. By admin / 03/08/2015
Ublituximab, a Novel Glycoengineered Anti-CD20 Monoclonal Antibody (mAb), in Combination with TGR-1202, a Next Generation Once Daily PI3K Delta Inhibitor, Demonstrate Activity in Heavily Pre-Treated and High-Risk Chronic Lymphocytic Leukemia (CLL) and B-Cell Lymphoma. By admin / 12/09/2014
The PI3K-delta Inhibitor TGR-1202 in Combination with Brentuximab Vedotin (SGN-35) Synergistically Inhibits Tubulin Polymerization and Exerts Potent Antitumor Effects in NOD/SCID Mice with Hodgkin Lymphoma Cell Line Xenografts. By admin / 12/09/2014
TGR-1202, a Novel Once Daily Pi3K Delta Inhibitor, Demonstrates Clinical Activity with a Favorable Safety Profile, Lacking Hepatotoxicity, in Patients with Chronic Lymphocytic Leukemia and B-Cell Lymphoma. By admin / 12/09/2014
Complementary Targeting of PI3K and the Proteasome Causes Potent Inhibition of mTORC1 and NF-kappaB in Models of B- and T-Cell Lymphoma. By admin / 12/09/2014
Activity of TGR-1202, a Novel Once-Daily Pi3K Delta Inhibitor, in Patients with Relapsed or Refractory Hematologic Malignancies. By admin / 06/13/2014
